# Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

> **NCT03171220** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **BIOLOGICAL:** Neoantigen Reactive T Cells(NRTs)
- **BIOLOGICAL:** SHR-1210
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Interleukin-2

## Key facts

- **NCT ID:** NCT03171220
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03171220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03171220, "Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03171220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*